Total US medical devices industry venture financing deals in Q4 2018 worth $1.45bn were announced, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 14.5% over the previous quarter and a drop of 15.4% when compared with the last four-quarter average of $1.75bn.
The United States held a 78.5% share of the global medical devices industry venture financing deal value that totalled $1.84bn in Q4 2018.
In terms of deal activity, the United States recorded 129 deals during Q4 2018, marking a rise of 0.8% over the previous quarter and a drop of 22.8% over the last four-quarter average.
US medical devices industry venture financing deals in Q4 2018: Top deals
The top five medical devices industry venture financing deals accounted for 42.5% of the overall value during Q4 2018.
The combined value of the top five medical devices industry venture financing deals stood at $614.5m, against the overall value of $1.45bn recorded for the quarter. The top announced medical devices industry venture financing deal tracked by GlobalData in Q4 2018 was Ireland Strategic Investment Fund, Sequoia Capital Operations, Temasek International and Yunfeng Capital’s $200m venture financing of WuXi NextCODE Genomics.
In second place was the $150m venture financing of Caris Life Sciences by TPG Sixth Street Partners and in third place was 8VC, Founders Fund and Menlo Ventures’ $110m venture financing of Synthego.
The $87m venture financing of EarLens by Aisling Capital, ARCH Healthcare Fund, Cochlear, CRG PARTNERS, Exor Seeds, Far East Ventures, GDN Holdings, KCK, LSV Capital Management, New Enterprise Associates, Relativity Healthcare Fund, Richard King Mellon Foundation, SightLine Partners, Vertex Healthcare and Windham Venture Partners and 5AM Venture Management, Kohlberg Kravis Roberts & Co, Norwest Venture Partners XII, venBio Partners and Vivo Capital’s venture financing of Impel NeuroPharma for $67.5m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.